New antileishmanial candidates and lead compounds.
Although miltefosine and paromomycin were registered as clinical agents against visceral leishmaniasis in the last decade, the antileishmanial drug arsenal still requires improvement, particularly in the area of oral antileishmanial drugs for both visceral and cutaneous diseases. Several new compounds and formulations have displayed promising efficacy in animal models of leishmaniasis, including the 8-aminoquinoline NPC1161, a series of bis-quinolines, DB766, rhodacyanine dyes, amiodarone, and an oral formulation of amphotericin B. Herein we provide a review of those molecules whose antileishmanial properties have been described over the past few years and a brief assessment of the studies required to identify new preclinical antileishmanial candidates.
Richard
Julian V
JV
Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA.
Werbovetz
Karl A
KA
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D007896:Leishmaniasis / Q000188:drug therapy*; D015394:Molecular Structure
D000981:Antiprotozoal Agents